Zobrazeno 1 - 10
of 271
pro vyhledávání: '"Paul W. H. I. Parren"'
Autor:
Haiyu Wang, Fleur S. van de Bovenkamp, Douwe J. Dijkstra, Leoni Abendstein, Nicole V. Borggreven, Jos Pool, Rob Zuijderduijn, Christoph Gstöttner, Kyra A. Gelderman, Timon Damelang, Gestur Vidarsson, Anna M. Blom, Elena Domínguez-Vega, Paul W. H. I. Parren, Thomas H. Sharp, Leendert A. Trouw
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Complement activation protects against infection but also contributes to pathological mechanisms in a range of clinical conditions such as autoimmune diseases and transplant rejection. Complement-inhibitory drugs, either approved or in development, u
Externí odkaz:
https://doaj.org/article/66693f5931e04cbdb02cb3b635c4eb80
Autor:
Willemijn van der Wulp, Anna M. Gram, Boris Bleijlevens, Renate S. Hagedoorn, Can Araman, Robbert Q. Kim, Jan Wouter Drijfhout, Paul W. H. I. Parren, Richard G. Hibbert, Rob C. Hoeben, Sander I. van Kasteren, Janine Schuurman, Maaike E. Ressing, Mirjam H. M. Heemskerk
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Therapeutic antibody-epitope conjugates (AECs) are promising new modalities to deliver immunogenic epitopes and redirect virus-specific T-cell activity to cancer cells. Nevertheless, many aspects of these antibody conjugates require optimization to i
Externí odkaz:
https://doaj.org/article/458e15a064ab40b08049bc6f97a6578d
Autor:
José Saura-Esteller, Milon de Jong, Lisa A. King, Erik Ensing, Benjamin Winograd, Tanja D. de Gruijl, Paul W. H. I. Parren, Hans J. van der Vliet
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
γδ T-cells directly recognize and kill transformed cells independently of HLA-antigen presentation, which makes them a highly promising effector cell compartment for cancer immunotherapy. Novel γδ T-cell-based immunotherapies, primarily focusing
Externí odkaz:
https://doaj.org/article/57a7fb13f9c9431cbab1118c84862f44
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Externí odkaz:
https://doaj.org/article/3fc074a0f69b4999a86dde83eaf5c13d
Autor:
Aran F. Labrijn, Joyce I. Meesters, Matthew Bunce, Anthony A. Armstrong, Sandeep Somani, Tom C. Nesspor, Mark L. Chiu, Işil Altintaş, Sandra Verploegen, Janine Schuurman, Paul W. H. I. Parren
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-14 (2017)
Abstract Therapeutic concepts exploiting tumor-specific antibodies are often established in pre-clinical xenograft models using immuno-deficient mice. More complex therapeutic paradigms, however, warrant the use of immuno-competent mice, that more ac
Externí odkaz:
https://doaj.org/article/bbef8d706f08451bb51dc1be0939cbc2
Autor:
Mario Losen, Aran F. Labrijn, Vivianne H. van Kranen-Mastenbroek, Maarten L. Janmaat, Krista G. Haanstra, Frank J. Beurskens, Tom Vink, Margreet Jonker, Bert A. ‘t Hart, Marina Mané-Damas, Peter C. Molenaar, Pilar Martinez-Martinez, Eline van der Esch, Janine Schuurman, Marc H. de Baets, Paul W. H. I. Parren
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Abstract Autoantibodies against ion channels are the cause of numerous neurologic autoimmune disorders. Frequently, such pathogenic autoantibodies have a restricted epitope-specificity. In such cases, competing antibody formats devoid of pathogenic e
Externí odkaz:
https://doaj.org/article/24f5b6bf021946909f7c67a223ec548b
Autor:
Simone C. Oostindie, Hilma J. van der Horst, Margaret A. Lindorfer, Erika M. Cook, Jillian C. Tupitza, Clive S. Zent, Richard Burack, Karl R. VanDerMeid, Kristin Strumane, Martine E. D. Chamuleau, Tuna Mutis, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Frank J. Beurskens, Paul W. H. I. Parren, Ronald P. Taylor
Publikováno v:
Haematologica, Vol 104, Iss 9 (2019)
CD20 monoclonal antibody therapies have significantly improved the outlook for patients with B-cell malignancies. However, many patients acquire resistance, demonstrating the need for new and improved drugs. We previously demonstrated that the natura
Externí odkaz:
https://doaj.org/article/8951ab20ead14f0a871191432d4962ce
Publikováno v:
Nature Reviews Drug Discovery, 21(10), 715-735. NATURE PORTFOLIO
Antibody function is dependent on avidity - the accumulated strength of multiple affinity interactions between the antibody, antigen, cell surface receptors and other antibodies. In this Review, Oostindie et al. discuss the role of avidity in eliciti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4da7678cb248273fc8dd627179fde8b
https://doi.org/10.1038/s41573-022-00501-8
https://doi.org/10.1038/s41573-022-00501-8
Publikováno v:
Nature reviews. Drug discovery. 21(10)
Antibodies are the cardinal effector molecules of the immune system and are being leveraged with enormous success as biotherapeutic drugs. A key part of the adaptive immune response is the production of an epitope-diverse, polyclonal antibody mixture
Autor:
Iris de Weerdt, Tanja D. de Gruijl, Jurjen M Ruben, Hans van Vliet, Mark-David Levin, Lisa A King, Roeland Lameris, Arnon P. Kater, Paul W. H. I. Parren, Renate de Boer, Jan Kloosterman
Publikováno v:
de Weerdt, I, Lameris, R, Ruben, J M, de Boer, R, Kloosterman, J, King, L A, Levin, M-D, Parren, P W H I, de Gruijl, T D, Kater, A P & van der Vliet, H J 2021, ' A bispecific single-domain antibody boosts autologous Vg9Vd2-T cell responses toward CD1d in chronic lymphocytic leukemia ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 27, no. 6, pp. 1744-1755 . https://doi.org/10.1158/1078-0432.CCR-20-4576
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical cancer research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical Cancer Research, 27(6), 1744-1755. AMER ASSOC CANCER RESEARCH
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical cancer research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical Cancer Research, 27(6), 1744-1755. AMER ASSOC CANCER RESEARCH
Purpose: Although considerable progress has been made with autologous T cell–based therapy in B-cell malignancies, application in chronic lymphocytic leukemia (CLL) lags behind due to disappointing response rates as well as substantial toxicity tha